Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Novo Nordisk A/S3,495 enrolled

Overview

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

Study Type

OBSERVATIONAL

Enrollment

3,495

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months * Analogue premix administration for the last 6 months Exclusion Criteria: * Known or suspected allergy to insulin aspart * Newly diagnosed diabetes

Locations (1)

Novo Nordisk Investigational Site

Budapest, Hungary

Outcomes

Primary Outcomes

HbA1C

Time frame: 6 months

Secondary Outcomes

General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.